HOME >> BIOLOGY >> NEWS
Novel therapeutic target identified in fight against Rheumatoid Arthritis

A team of scientists, led by Toshihiro Nakajima at the St Marianna University School of Medicine in Japan, has identified an exciting therapeutic target that may lead to the development of new treatments for Rheumatoid Arthritis (RA).

As published in the latest edition of Genes and Development, the scientists report the discovery of 'synoviolin', an enzyme that is found in abnormally high levels in diseased joints. High levels of synoviolin are found to cause an overgrowth of joint-destroying synovial cells, a key clinical feature of RA. By reducing levels of synoviolin, scientists hope to halt the proliferation of synovial cells and the devastating progression of RA.

RA is one of the most common joint diseases, affecting approximately 0.5-1.0% of the adult population worldwide. The progressive joint destruction, which mainly targets the small joints of the hands and feet, eventually results in severe movement disability. The clinical features of RA include chronic inflammation of the synovium, or lining of the joint, accompanied by the overgrowth of synovial cells, a condition known as synovial hyperplasia. This mass of synovial cells, or 'pannus', eventually invades and destroys the cartilage and bone within the joint. Clearly, understanding the factors that regulate synovial hyperplasia are key to designing new therapies to treat RA.

Dr Nakajima and colleagues set out to identify proteins found in synovial cells from rheumatoid joints, with the hope of discovering novel pathogenic factors involved in RA. Using an antibody screening approach, the scientists identified synoviolin as an enzyme that is upregulated in synovial tissues from RA patients. To elucidate the function of synoviolin, the team engineered mice that produced an excess of synoviolin. Significantly, these mice developed spontaneous arthritic joint disease, suggesting that too much synoviolin is indeed an important factor in the development of RA. They also gener
'"/>

Contact: Heather Cosel
coselpie@cshl.org
Cold Spring Harbor Laboratory
16-Sep-2003


Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel bacterium detoxifies chlorinated pollutants
9. Novel flu vaccine shows promise in mice
10. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician
11. Novel method identifies hidden genes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/1/2020)... ... ... More than 600 people undergo genetic counseling and testing each year as ... two genetic counselors. , My Gene Counsel , a digital health company that ... Rick Program to ensure that UConn’s patients who have undergone genetic testing for cancer ...
(Date:4/30/2020)... ... 29, 2020 , ... At the start of 2020 ... for a wide range of industries including pharmaceutical and biopharmaceutical manufacturing, healthcare, food ... new decade, it was clear to company leadership that they would have to ...
(Date:4/26/2020)... NEW YORK (PRWEB) , ... April 23, 2020 , ... ... collaboration with GenScript, is developing a synthetic antibody to SARS-CoV-2, the virus that causes ... lung cells, and would be another potential treatment option for COVID-19. , The efforts ...
Breaking Biology News(10 mins):
(Date:5/15/2020)... ... , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to ... Ganz will continue to lead Sentien’s Board of Directors, a role he has filled ... and Sentien’s management team. , Mr. Ganz has more than 30 years ...
(Date:5/14/2020)... , ... May 13, 2020 , ... ... assays or phenotypic readouts, providing little or no information on the drug’s mechanism ... more comprehensive characterization of compounds by measuring the activity of molecular pathways. This ...
(Date:5/5/2020)... Fla. (PRWEB) , ... May 05, 2020 , ... ... and solutions company, announced today the launch of its iGlucose® LTE ... new iGlucose solution utilizes LTE Cat-M1 technology, the industry’s newest and broadest cellular ...
(Date:4/22/2020)... and CAMBRIDGE, Mass. (PRWEB) , ... April 20, ... ... Budapest with US offices in Cambridge, MA, announced today that Omixon’s founder and ... the early commercialisation of Omixon’s flagship product Holotype HLA since 2014 before stepping ...
Breaking Biology Technology:
Cached News: